Alira Health Welcomes Marie-Aude Ohresser, Vice President, Regulatory Affairs

News
Category:
Published on:
May 5, 2020

BOSTON, USA – Alira Health (www.alirahealth.com), a leading international healthcare and life sciences advisory firm, announces the appointment of Marie-Aude Ohresser to Vice President, Regulatory Affairs. Based in our Basel, Switzerland office, Marie-Aude will be instrumental in bolstering our EU regulatory capabilities as well as offering more comprehensive regulatory support globally.

Marie-Aude Ohresser

“We are delighted to welcome Marie-Aude to our Alira Health family. Marie-Aude joins us with a rich background and knowledge in the pharmaceutical industry including drug development, gene therapy, and various areas of regulatory affairs,” said Giacomo Basadonna, Chief Medical Officer, Alira Health. “Marie-Aude’s recruitment represents a fundamentally important step forward in expanding Alira Health’s global presence as a leading force in Regulatory Affairs for Pharma Products and Medical Devices, with the goal of transforming health care delivery for the benefit of patients around the world.”

“At this point in my career, I am ready for new challenges, and Alira Health is a perfect match for me. My new colleagues are dynamic, agile, and diligent and foster a supportive work environment,” said Marie-Aude. “I look forward to building on Alira Health’s existing pharma regulatory services as well as continuing to grow the synergies with our other divisions. I am confident that we are creating something extraordinary here, and the sky is the limit.”

Marie-Aude has over 20 years of experience in product development for the pharmaceutical industry. For the last decade, she worked with F. Hoffmann-La Roche, Ltd. as the Head of EU Liaison, Global Regulatory Affairs where she was responsible for planning and implementing strategy and activities such as optimizing resources and processes, developing KPIs, strengthening collaboration between affiliates and global regulatory departments to meet business needs. Marie-Aude has also led various cross-functional projects in the areas of regulatory records management and the pharmacovigilance system master file.

Most recently, Marie-Aude led changes related to Brexit across Roche’s pharmaceutical division. Prior to this, Marie-Aude was a regulatory strategist at Transgene SA and a project lead for a therapeutic vaccine in oncology. Marie-Aude has extensive knowledge of EU regulatory procedures and hands-on experience in preparing high-quality regulatory documentation.

To learn more about Marie-Aude, contact us.

Related news

Multimedia September 29, 2022
Regulatory Strategy for Registering Rare Disease Products in the EU
In this webinar we will focus on how to benefit, today and in the future, from the orphan drug program and build a regulatory strategy for successful rare disease product registration(...)
Drug Development Rare Disease Regulatory
Publications August 4, 2022
White Paper: New European Health Technology Assessment Regulation
In this white paper, we provide an overview of this new regulation, including key points of the new European Health Technology Assessment Regulation, its methodology, and its timelines.
MedTech Regulatory
Publications July 15, 2022
How to leverage registry-based studies to generate high-quality Real-World Evidence
The use of Real-World Evidence (RWE) in regulatory decision making will support the development and application of better medicines.
Real-World Evidence Registry-based studies Regulatory RWE
Publications July 14, 2022
How to successfully use the EMA IRIS portal to ensure timely submissions
Submitting your scientific advice (SA), orphan drug designation (ODD) or Innovation Task Force (ITF) consultation to the EMA? Avoid delays with our submission recommendations.
European Medicines Agency Orphan Drug Regulatory
Multimedia July 12, 2022
Webinar Replay: What You Should Know About MDR Best Practices, Including PMCF
Discover the major changes introduced by the MDR, including the post-market requirements, and especially the Post-Market Clinical Follow-up (PMCF).
MedTech Regulatory
Events June 30, 2022
DTx France 2022
We are pleased to announce that we will be joining as speakers and exhibitors at DTx France 2022. This hybrid event will focus on the latest DTx trends, regulatory framework, market(...)
DTx trends Market Access Regulatory
Events May 19, 2022
DIA 2022 Global Annual Meeting
We are pleased to announce that we will be joining DIA 2022 Global Annual Meeting as exhibitors and delegates.
Biometrics Clinical Life Sciences Regulatory
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.